On May 14, 2019 Novocure (NASDAQ: NVCR) reported 13 presentations and a symposium on Tumor Treating Fields at the 70th Annual Meeting of the German Society of Neurosurgery (DGNC) on May 12 through May 15 in Würzburg, Germany (Press release, NovoCure, MAY 14, 2019, View Source [SID1234536280]). The presentations are part of a Tumor Treating Fields session, which is a first for Novocure at this conference. Of the presentations, six are oral presentations and seven are posters. A lunch symposium will feature seven speakers on Tumor Treating Fields-related topics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that Tumor Treating Fields has become a significant part of the dialogue at DGNC," said Thomas Hefti, Vice President of Europe and Emerging Markets at Novocure. "DGNC provides a forum for the exchange of important scientific information. We look forward to sharing our science on Tumor Treating Fields and contributing to the discussion."

Oral Presentations

(V001) The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER – TTFields in Germany in routine clinical care). O. Bähr (Frankfurt am Main, Frankfurt), M. Glas (Essen). 8 to 8:10 a.m. CEST May 13
Studie zur Anwendung von TTFields in der klinischen Routine, bei Patientinnen und Patienten mit einem neudiagnostizierten Glioblastom in Deutschland (TIGER Studie).

(V002) Tumour-treating fields (TTF) with different settings in different glioma cell lines. G. Hatipoglu Majernik (Hannover). 8:10 to 8:20 a.m. CEST May 13
Tumortherapiefelder (TTF) mit unterschiedlichen Einstellungen in verschiedenen Gliomzelllinien

(V003) The blood brain barrier (BBB) permeability is altered by tumour treating fields (TTFields) in vitro and in vivo. E. Salvador (Würzburg). 8:20 to 8:30 a.m. CEST May 13
Die Permeabilität der Blut-Hirn-Schranke wird durch Tumor Treating Fields (TTFields) in vitro und in vivo beeinflusst

(V004) The effect of tumour treating fields on cell morphology and invasion of different cancer cells. A. Kinzel (München). 8:30 to 8:40 a.m. CEST May 13
Die Wirkung von Tumortherapiefeldern auf die Zellmorphologie und Invasion verschiedener Tumorzellen

(V005) Increased survival benefit for newly diagnosed glioblastoma patients with higher TTFields doses to the tumour bed. Z. Bomzon (Haifa, IL). 8:40 to 8:50 a.m. CEST May 13
Höhere TTFields Dosen im Tumorbett erhöhen den Überlebensvorteil bei Patienten mit einem neu diagnostizierten Glioblastom

(V006) Open-label phase 1 clinical trial testing personalised and targeted skull remodelling surgery to maximise TTFields intensity for recurrent glioblastoma – interim analysis and safety assessment (OptimalTTF-1). N. Mikic (Aarhus, DK). 8:50 – 9 a.m. CEST May 13
Open-label Phase 1 Studie zur Untersuchung einer personalisierten und zielgerichteten Remodellierungsoperation zur Maximierung der TTFields lntensität beim rezidivierenden Glioblastom – Interim-Analyse und Sicherheitsbewertung (OptimalTTF-1).

Poster Presentations

(P169) The dielectric properties of intracranial tumours. M. Proescholdt (Regensburg). 1:35 to 1:40 p.m. CEST May 14
Die bioelektrischen Eigenschaften von intrakraniellen Tumoren

(P201) Aurora kinase inhibition to enhance tumour treating fields (TTFields) efficacy in glioblastoma treatment. D. Krex (Dresden). 1:20 to 1:25 p.m. CEST May 14
Die Inhibition von Aurora-Kinasen erhöht die Effektivität einer Behandlung mit Tumor Treating Fields bei Glioblastom-Patienten

(P202) Simulation of TTFields distribution within patient-specific computational head models. Z. Bomzon (Haifa, IL) 1:25 to 1:30 p.m. CEST May 14
Simulation der TTFields Verteilung in patientenspezifischen Kopfmodellen

(P203) PriCoTTF – a phase I/II trial of tumour treating fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. L. Lazaridis (Essen). 1:30 to 1:35 p.m. CEST May 14
PriCoTTF – eine Phase I/II Studie zu Tumortherapiefeldern vorausgehend und konkomitant zu Strahlentherapie und Temozolomid im neudiagnostizierten Glioblastom

(P205) Safety and adverse event profile of tumour treating fields in elderly patients – a post-market surveillance analysis. L. Lazaridis (Essen). 1:40 to 1:45 p.m. CEST May 14
Sicherheitsprofil von Tumortherapiefeldern (TTFields) in älteren Patienten – eine Post-Market Surveillance Analyse

(P206) Safety and adverse event profile of tumour treating fields use in the EMEA region – a real-world data analysis. L. Lazaridis (Essen) 1:45 to 1:50 p.m. CEST May 14
Sicherheitsprofil von Tumortherapiefeldern (TTFields) in der EMEA Region – Datenanalyse aus der klinischen Routine

(P207) Effect of tumour-treating fields plus chemotherapy in patients with recurrent glioblastoma. P. Spindler (Berlin) 1:50 to 1:55 p.m. CEST May 14
Der Effekt von ‘tumor-treating fields’ als Zugabe zu Chemotherapie in Patienten mit Glioblastom-Rezidiv

Lunch Symposium

12:15 to 1:15 p.m. CEST May 14

• D. Krex: Aurora kinase inhibition in combination with tumour treating fields (TTFields) (German)
Aurora-Kinase-Inhibierung in Kombination mit Tumortherapiefeldern (TTFields)

• L. Lazaridis: Clinical experience with the combination of TTFields with CCNU/TMZ (CeTeG) (German)
Klinische Erfahrungen mit der Kombination von TTFields und CCNU/TMZ

• C. Kramm: TTFields in pediatric patients
TTFields bei pädiatrischen Patienten

• M. Stein: Proton boost and Optune therapy in glioblastoma
Protonenboost- und Optune-Therapie beim Glioblastom

• M. Glas: TTFields and radiation – recent data and clinical developments
TTFields in Kombination mit Strahlentherapie – aktuelle Daten und klinische Entwicklungen

• M. Proescholdt: Comptune: Identification of parameters relevant for compliance in TTFields therapy
Comptune: Identifikation compliance-relevanter Parameter bei TTFields Behandlung

• A. Kessler: Experience with TTFields and meetings of patients using TTFields in Wuerzburg (German)
Erfahrungen mit TTFields und Patiententreffen von TTFields Patienten in Würzburg